OPEN ACCESS Freely available online

ISSN: 2153-2435
Pharmaceutica Analytica Acta

Commentary

Pharmaceutical Formulation: A Quantitative Model-Based Approach

Mayeren Thomet*

Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada

DESCRIPTION

Pharmaceutical formulation is the process of designing and developing drug products that deliver the Active Pharmaceutical Ingredient (API) in a safe, effective, and convenient way. Pharmaceutical formulation involves selecting the appropriate excipients, dosage forms, manufacturing methods, and quality control measures to ensure the quality, stability, bioavailability, and performance of the drug product.

A quantitative model-based approach to pharmaceutical formulation is a systematic and rigorous method that uses mathematical models to describe the relationships between the formulation factors, process variables, and product responses. A quantitative model-based approach can help to optimize the formulation conditions, reduce the number of experiments, identify the critical quality attributes, and support the regulatory submissions. It requires a multidisciplinary team of experts from different fields, such as pharmaceutics, pharmacology, biostatistics, mathematics, engineering, and computer science. A quantitative model-based approach can be applied at different stages of pharmaceutical formulation development, such as pre-formulation, formulation screening, scale-up, and stability testing.

Physicochemical models

These models describe the physical and chemical properties of the API and the excipients, such as solubility, partition coefficient, dissolution rate, degradation kinetics, etc. Physicochemical models can help to predict the impact of formulation factors on the stability and bioavailability of the drug product.

Pharmacokinetic models

These models describe the Absorption, Distribution, Metabolism, and Excretion (ADME) of the drug in the body. Pharmacokinetic models can help to predict the plasma concentration-time profiles of the drug and its metabolites after administration of different dosage forms.

Pharmacodynamics models

These models describe the relationship between the drug concentration at the site of action and the pharmacological effect. Pharmacodynamics models can help to predict the efficacy and safety of the drug product for different patient populations and disease states.

Systems pharmacology models

These models integrate the pharmacokinetic and pharmacodynamics models with mechanistic information on the biological pathways and networks involved in the drug action. Systems pharmacology models can help to understand the complex interactions between the drug, the disease, and the host factors, and to identify biomarkers and surrogate endpoints. Defining the problem and objectives to the team and it should clearly state the research question and hypothesis, identify the target product profile and performance criteria, and define the scope and assumptions of the model.

Developing and validating the model

The team should select or develop an appropriate model structure based on existing knowledge and data sources. The model parameters should be estimated or calibrated using experimental or clinical data. The model should be validated by comparing its predictions with independent data sets or alternative methods. Applying and refining the model to perform simulations or optimizations to answer the research question or hypothesis. The model predictions should be interpreted in light of their uncertainty and sensitivity. The model should be refined or updated as new data or knowledge become available.

Communicating and documenting the model

The team should report and document the model development process, assumptions, limitations, results, conclusions, and recommendations in a clear and transparent way. The team should also share or publish the model code and data for peer review or reuse.

Correspondence to: Mayeren Thomet, Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada, E-mail: mayerenthomet@gmail.com

Received: 03-Apr-2023, Manuscript No. PAA-23-21210; **Editor assigned:** 07-Apr-2023, Pre QC No. PAA-23-21210 (PQ); **Reviewed:** 21-Apr-2023, QC No PAA-23-21210; **Revised:** 28-Apr-2023, Manuscript No. PAA-23-21210 (R); **Published:** 04-May-2023, DOI: 10.35248/2153-2435.23.14.729

Citation: Thomet M (2023) Pharmaceutical Formulation: A Quantitative Model-Based Approach. Pharm Anal Acta. 14:729.